Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.

Trinity Health Muskegon recently achieved a significant milestone by successfully implanting AVEIR DR, the world’s first dual-chamber leadless pacemaker system designed to effectively treat abnormal ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

That test could help identify patients at greatest risk for potentially deadly cardiac problems such as coronary artery disease, atrial fibrillation (irregular heartbeat) and heart failure, and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Cedars-Sinai shared the story of a Hollywood writer who kept his appointment for mitral valve surgery right after escaping ...